Latest News of BMY
What's Next For BMY Stock After An Upbeat Q3?
By Forbes |
23 hours ago
Bristol Myers Squibb exceeded Q3 revenue and earnings estimates, raising its full-year outlook. The stock gained 6% in a week. Revenue grew 8% y-o-y, with strong performance in growth portfolio. Adjus...
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
By Yahoo! Finance |
3 days ago
The article discusses the current state of the pharmaceutical industry, highlighting the growth potential and challenges faced by companies like Bristol-Myers Squibb. It emphasizes the importance of b...
Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is 'Too Low'
By Yahoo! Finance |
1 week ago
Jim Cramer advises investors on upcoming earnings and nonfarm payroll report's impact on interest rates. Market conditions suggest caution and potential for a Fed rate cut. He stresses the significanc...
-
Bloomsbury Publishing's (LON:BMY) Dividend Will Be £0.0389
By Yahoo! Finance | 1 week agoBloomsbury Publishing Plc will pay a dividend of £0.0389 per share on November 29th, with a 1.9% yield. Despite a potential decrease in EPS, the dividend is well-covered by earnings....
-
We Ran A Stock Scan For Earnings Growth And Bloomsbury Publishing (LON:BMY) Passed With Ease
By Yahoo! Finance | 2 weeks agoMany investors are drawn to loss-making companies with a good story, but sustained losses can lead to investor losses. It's essential to consider profitability when investing, like in Bloomsbury Publi...
-
Bristol-Myers Squibb Company (BMY): A Buzzing AI Health Stock to Add to Your Portfolio
By Yahoo! Finance | 1 month agoDiscover the top 10 AI health stocks, including Bristol-Myers Squibb Company, amid AI's transformative impact on healthcare and economy. AI is set to revolutionize diagnostics, treatment, and operatio...
-
Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
By Yahoo! Finance | 1 month agoThe article discusses the importance of dividend achievers in investment strategies, focusing on Bristol-Myers Squibb Company (BMY) as a top performer with strong growth potential and consistent cash ...
-
BMY Stock Signals Breakout As FDA OKs Schizophrenia Drug
By Investor's Business Daily | 1 month agoBristol-Myers Squibb received FDA approval for Cobenfy, a groundbreaking schizophrenia drug that doesn't block dopamine directly. The stock surged as a result....
-
Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024
By Yahoo! Finance | 1 month agoThe article highlights Bristol-Myers Squibb Company's strong dividend history and growth potential amidst challenges faced by short sellers in the market. Despite recent acquisitions and stock drops, ...
-
Investors Should Be Encouraged By Bloomsbury Publishing's (LON:BMY) Returns On Capital
By Yahoo! Finance | 1 month agoTo identify a potential multi-bagger, look for businesses with increasing Return on Capital Employed (ROCE) and growing capital employed. Bloomsbury Publishing shows a 20% ROCE, higher than the indust...
-
Is Bristol-Myers Squibb Company (BMY) The Best Beaten Down Dividend Stocks to Invest in Now?
By Yahoo! Finance | 2 months agoBristol-Myers Squibb (NYSE:BMY) is a top beaten-down dividend stock. Despite challenges, dividend stocks remain strong, attracting investors with stable business models and cash flows. BMY offers soli...
-
Bloomsbury Publishing's (LON:BMY) investors will be pleased with their splendid 259% return over the last five years
By Yahoo! Finance | 2 months agoInvesting in stocks can yield gains exceeding 100% or result in a complete loss. Bloomsbury Publishing saw its stock price surge by 214% in five years. Examining EPS growth and shareholder returns is ...
-
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
By Yahoo! Finance | 3 months agoBristol-Myers Squibb Co has shown strong financial performance and innovation in drug development, especially in immuno-oncology. Despite U.S. market dependence and patent challenges, global expansion...
-
Investors in Bristol-Myers Squibb (NYSE:BMY) from three years ago are still down 30%, even after 5.4% gain this past week
By Yahoo! Finance | 3 months agoBristol-Myers Squibb stock has significantly underperformed the market in the last three years, with a 38% decrease in share price. Despite recent improvements, long-term shareholders are still in the...
-
Bloomsbury Publishing Plc (LON:BMY) Shares Could Be 34% Below Their Intrinsic Value Estimate
By Yahoo! Finance | 3 months agoBloomsbury Publishing Plc (LON:BMY) is currently undervalued by 34% according to the DCF model, with an intrinsic value estimate of UK£8.84 per share, compared to the current price of UK£7.1....